Download PDF
Thromb Haemost 1997; 78(02): 930-933
DOI: 10.1055/s-0038-1657654
Rapid Communication
Schattauer GmbH Stuttgart

Plasma Derived von Willebrand Factor Preparations: Collagen Binding and Ristocetin Cofactor Activities

Ping Chang
The Division of Hematology, George Washington University Medical Center, Washington D. C., USA
,
D L Aronson
The Division of Hematology, George Washington University Medical Center, Washington D. C., USA
› Author Affiliations
Further Information

Publication History

Received 31 1996

Accepted after revision 25 March 1997

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Five plasma preparations (11 lots) used in the treatment of von Willebrand’s disease (vWD) were evaluated. The collagen binding function of von Willebrand factor (vWF) containing preparations was compared with the ristocetin cofactor activity and the vWF antigen. Some preparations have higher ratio of functional activity (ristocetin cofactor and collagen binding) relative to the antigen than is found in normal plasma. The ristocetin cofactor activity and the collagen binding activity are tightly correlated (r = .95). Ultracentrifugal (UCF) analysis was used to compare the size distribution of vWf antigen, ristocetin cofactor and collagen binding activity. The sedimentation of all of the vWF parameters in the plasma products was slower than in plasma. In plasma products the ristocetin cofactor activity sediments the most rapidly, the collagen binding activity is slower and the antigen the slowest. The collagen/antigen ratio decreases with decreasing vWF size. Assignment of potency to vWF containing preparations utilizing the collagen binding activity may be more precise and as accurate as with the traditional ristocetin cofactor assay.

 

  • References

  • 1 Mannucci PM. Biochemical characteristic of therapeutic plasma concentrates used in the treatment of von Willebrand’s disease. Haemostasis 1994; 24: 285-288
    PubMedGoogle Scholar
  • 2 Berntorp E. Plasma product treatment in various type of von Willebrand’s disease. Haemost 1994; 24: 289-297
    CrossrefPubMedGoogle Scholar
  • 3 Fricke W, Yu M. Characterization of von Willebrand factor in factor VIII concentrates. Am J Haematol 1989; 31: 41-45
    CrossrefPubMedGoogle Scholar
  • 4 Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet activating factor. J Lab Clin Med 1975; 85: 318
    PubMedGoogle Scholar
  • 5 Howard MA, Firkin BG. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Hemorrh 1972; 26: 362-369
    PubMedGoogle Scholar
  • 6 Brown JE, Bosak JO. An ELISA test for binding of von Willebrand factor antigen to collagen. Thromb Res 1986; 43: 303-311
    CrossrefPubMedGoogle Scholar
  • 7 Favaloro EJ, Gripso L, Exner T, Koutts J. Development of a simple collagen-based ELISA aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II von Willebrand’s disease. Blood Coagulation and Fibrinolysis 1991; 02: 285-291
    CrossrefPubMedGoogle Scholar
  • 8 Lawrie AS, Harrison P, Armstrong AL, Wilboum BR, Dalton RG, Savidge GF. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates. Brit J Haemat 1989; 73: 100-104
    CrossrefPubMedGoogle Scholar
  • 9 Chang P, Aronson DL. A microtiter plate reader assay for factor VIII. Thromb Res 1992; 66: 599-602
    CrossrefPubMedGoogle Scholar
  • 10 Puri S, Gresham C, Kao KJ. A simple quantitative assay for ristocetin cofactor activity using microtiter plates and ELISA plate reader. Thrombosis Research 1994; 74: 285-291
    CrossrefPubMedGoogle Scholar
  • 11 Scharrer IM, Vigh T, Aygoren-Pursun E. Experience with Haemate P in von Willebrand’s disease in adults. Haemost 1994; 24: 298-303
    CrossrefPubMedGoogle Scholar
  • 12 Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickies FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand’s disease. Thromb Haemost 1994; 71: 173-179
    PubMedGoogle Scholar
  • 13 Retzios A, Arkel Y, Bhattacharya P, Bray G, Gringeri A, Lipton R, Mannucci PM, Tradati F. Efficacy and safety of Alpha 8R in the treatment of von Willebrand’s disease. Thromb Haemost 1993; 69: 2304 (abstract)
    PubMedGoogle Scholar
  • 14 Pasi KJ, Williams MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand’s disease patients with heat- treated factor VIE concentrate (BPL 8Y). Brit J Haemat 1990; 75: 228-233
    CrossrefPubMedGoogle Scholar
  • 15 Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation of a von Willebrand factor concentrate with low factor VIII activity. Brit J Haemat 1992; 80: 214-221
    CrossrefPubMedGoogle Scholar
  • 16 Aronson DL, Chang P. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations. Vox Sang 1995; 69: 08-13
    CrossrefPubMedGoogle Scholar
  • 17 Foster PA. A perspective on the use of factor VIII concentrates and cryo- precipitate prophylacticaly in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP. Thromb Haemost 1995; 74: 1370-1378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Boda Z, Pflieger G, Harsfalvi J, Rak K. Treatment of the severe bleeding episode in type ID von Willebrand’s disease by simultaneous administration of cryoprecipitate and platelet concentrate. Blood Coag and Fibrinolysis 1991; 02: 775-777
    PubMedGoogle Scholar
  • 19 Bloom AL, Peake IR, Furlong RA, Davies BL. High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand’s disease and inhibitor. Thromb Res 1979; 16: 847-852
    CrossrefPubMedGoogle Scholar
  • 20 Green D, Potter EV. Failure of AHF concentrate to control bleeding in VWD. Am J Med 1976; 10: 357-360
    PubMedGoogle Scholar
  • 21 Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand’s disease: Dissociation of bleeding time factor and ristocetin-cofactor activities. JAMA 1976; 236: 2770-2772
    CrossrefPubMedGoogle Scholar
  • 22 Weinstein M, Deykin D. Comparison of factor-VIE related von Willebrand proteins prepared from human cryoprecipitate and factor VIII concentrate. Blood 1979; 53: 1095-1105
    PubMedGoogle Scholar
  • 23 Martin SE, Marder VJ, Francis CW, Barlow GH. Structural studies on the functional heterogeneity of von Willebrand protein polymers. Blood 1981; 57: 313-323
    PubMedGoogle Scholar
  • 24 Sixma JJ, Sakariassen KS, Beeser Visser. Adhesion of platelets to human artery subendothelium: effect of factor VUI-von Willebrand factor of various multimeric composition. Blood 1984; 63: 128-138
    PubMedGoogle Scholar
  • 25 Fischer BE, Kramer G, Mitterer A, Grillberger L, Reiter M, Mundt W, Domer F, Eibl J. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84: 55-66
    CrossrefPubMedGoogle Scholar
  • 26 Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994; 83: 3018-3027
    PubMedGoogle Scholar
  • 27 Hathaway WE, Mahasandana C, Clarke S, Humbert JR. Paradoxical bleeding in intensively transfused hemophiliacs: alteration of platelet function. Transfusion 1973; 13: 06-12
    CrossrefPubMedGoogle Scholar
  • 28 Jakab T, Pflugshaupt R, Furlan M, Beck EA. Variable degradation of factor-VIII related protein in lyophilised concentrates of antihemophilic factor (AHF). Vox Sang 1978; 35: 36-40
    CrossrefPubMedGoogle Scholar